VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
QTEX
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
QTEXQTREX Quantum Ltd.
$1.09$45M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
  1. Home
  2. Financial Ratios

  1. Home
  2. Stocks
  3. QTEX
  4. Financial Ratios

QTREX Quantum Ltd. (QTEX) Financial Ratios

Latest Ratios: P/E Ratio -2.3x · EV/EBITDA 4.5x · ROE -397.9%. (2018–2025 historical series)

Income StatementBalance SheetCash FlowRatios
AnnualQuarterly

QTEX Valuation Multiples

Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Market Cap$61M$27M$19M$13M$14M$22M———
Enterprise Value$59M$25M$16M$9M$9M$-192104———
P/E Ratio →-2.31————————
P/S Ratio210.1192.25———————
P/B Ratio13.9011.484.372.231.091.08———
P/FCF—————————
P/OCF—————————

P/E links to full P/E history page with 30-year chart

QTEX EV Ratios

Enterprise-value multiples — capital-structure-neutral measures of total business value

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
EV / Revenue—86.39———————
EV / EBITDA4.48—1423.49—0.57————
EV / EBIT—————————
EV / FCF—————————

QTEX Profitability

Margins and return-on-capital ratios measuring operating efficiency

Margins

Full margin charts and quarterly trend are on the Earnings History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Gross Margin-94.1%-94.1%——107.7%————
Operating Margin-4710.7%-4710.7%——-318.4%————
Net Profit Margin-4574.4%-4574.4%——85.5%————

Return on Capital

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
ROE-397.9%-397.9%-0.2%-121.6%-24.1%-181.9%———
ROA-197.2%-197.2%-0.1%-89.1%-19.1%-126.3%-1062.9%-2381.3%-360.0%
ROIC-870.5%-870.5%0.5%-200.7%400.2%—-4274.3%-2978.9%—
ROCE-377.3%-377.3%0.2%-117.4%83.0%-112.7%-17413.9%——

QTEX Leverage & Debt

Solvency and debt-coverage ratios — lower is generally safer

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Debt / Equity0.670.670.580.150.110.07———
Debt / EBITDA——219.18—0.10————
Net Debt / Equity—-0.73-0.60-0.73-0.42-1.09———
Net Debt / EBITDA——-227.66—-0.35————
Debt / FCF————————-1.67
Interest Coverage-1512.67-1512.67—-1127.60-82.74-2822.67-1432.40-507.33—

Net cash position: cash ($3M) exceeds total debt ($2M)

QTEX Liquidity & Efficiency

Short-term solvency ratios and asset-utilisation metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Current Ratio1.561.562.022.618.725.680.720.040.28
Quick Ratio1.301.301.892.618.895.600.720.030.35
Cash Ratio1.151.151.712.478.375.510.520.020.20
Asset Turnover—0.05——-0.29————
Inventory Turnover0.760.761.10——0.65—2.17—
Days Sales Outstanding—————————

QTEX Shareholder Yields

Earnings, FCF, buyback, and dividend yields — total returns to shareholders

Dividends

Full dividend history and growth charts are on the Dividend History page

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Dividend Yield—————————
Payout Ratio—————————

Total Shareholder Return Metrics

MetricTTMFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Earnings Yield—————————
FCF Yield—————————
Buyback Yield0.0%0.0%0.0%0.0%0.0%0.0%———
Total Shareholder Yield0.0%0.0%0.0%0.0%0.0%0.0%———
Shares Outstanding—$30M$19M$12M$11M$5M$7M$14M$2M

Key Metrics

Growth RegimeMixed
ProfitabilityNegative
Balance SheetVulnerable
Cash FlowBurning
Top Statement Risk

Capital dilution and regulatory failure

Speculative Valuation Reflects Regulatory Hopes

With a price-to-sales ratio of 186.27, IINN's valuation appears untethered from current fundamentals, as reported in recent financial data, suggesting that market participants are pricing in a binary outcome regarding the successful commercialization of the ART system rather than any near-term earnings potential or historical revenue growth.

The extreme P/S multiple indicates that investors are valuing the company as a high-stakes option on future regulatory approval rather than a traditional medical device manufacturer. This valuation level warrants caution, as it implies a massive future market share that remains entirely contingent on clinical trial success and subsequent physician adoption.

Capital Efficiency Obscured by Losses

Based on the provided financial figures, the company's ROIC has fluctuated wildly between 52.6% and -72.9% over the last ten quarters, reflecting the inherent volatility of a pre-revenue firm where small changes in R&D spending or asset base cause massive swings in return metrics.

These erratic returns on capital suggest that traditional efficiency metrics are currently meaningless for assessing management's performance. Investors should monitor the stability of these figures only after the company achieves a consistent revenue base, as current data points are heavily distorted by the ongoing, non-recurring nature of clinical development costs.

Working Capital Cycles Remain Nascent

As indicated by the reported inventory days of 451 in 2025Q2, the company's working capital efficiency is currently in a state of extreme stagnation, which is typical for a firm that has yet to establish a repeatable, high-volume manufacturing or distribution process for its proprietary medical devices.

The high inventory turnover duration suggests that the company is holding significant prototype or pilot-stage components that are not yet moving through a commercial supply chain. This lack of velocity in the cash conversion cycle highlights the operational gap between current research activities and the requirements for a scalable commercial business model.

Liquidity Buffer Nearing Critical Threshold

According to the latest quarterly filings, the current ratio has compressed to 1.15, signaling that the company's ability to cover short-term obligations is rapidly diminishing as it continues to burn through its limited cash reserves to fund ongoing clinical and regulatory development efforts.

The narrowing liquidity position suggests that the company may face significant pressure to secure additional financing in the near term. Investors should monitor the quick ratio closely, as any further decline could indicate an inability to sustain operations without immediate, potentially dilutive, capital market intervention.

Misapplied P/E Ratio Obscures Reality

The price-to-earnings ratio is the most commonly misapplied metric for IINN, as the company's negative earnings and pre-commercial status render traditional valuation multiples fundamentally irrelevant for assessing the firm's true potential or its current financial health in the context of its development-stage business model.

Using P/E to evaluate a company that is currently burning cash to fund R&D provides no insight into the value of its intellectual property or the probability of regulatory success. Analysts should instead focus on the cash runway and the progress of clinical milestones, which are the true drivers of value for this specific medical device entity.

Download Financial Ratios Data

Includes 30+ ratios · 8 years · Updated daily

Consensus & Technical Research Suite
Open QTEX Terminal

QTEX Chart Terminal

WASM

Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.

Launch Terminal

Live Breakouts Feed

LIVE

High-probability breakout stocks crossing their pivot across 5 pattern engines.

Explore Setups

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

10-year return with dividends reinvested.

Calculate

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

QTEX — Frequently Asked Questions

Quick answers to the most common questions about buying QTEX stock.

What is QTREX Quantum Ltd.'s P/E ratio?

QTREX Quantum Ltd.'s current P/E ratio is -2.3x. This places it at the 50th percentile of its historical range.

What is QTREX Quantum Ltd.'s EV/EBITDA?

QTREX Quantum Ltd.'s current EV/EBITDA is 4.5x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 0.6x.

What is QTREX Quantum Ltd.'s ROE?

QTREX Quantum Ltd.'s return on equity (ROE) is -397.9%. The historical average is -145.1%.

Is QTEX stock overvalued?

Based on historical data, QTREX Quantum Ltd. is trading at a P/E of -2.3x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.

What are QTREX Quantum Ltd.'s profit margins?

QTREX Quantum Ltd. has -94.1% gross margin and -4710.7% operating margin.